Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban and Atorvastatin for Myocardial Injury After Noncardiac Surgery
NCT06961630Phase 1Recruiting
- Sponsor
- NYU Langone Health
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban and atorvastatin in Myocardial injury (2 arms), sponsored by NYU Langone Health. Primary endpoint: Percentage of pills taken at 6 months. Started Oct 2025; status: recruiting.
02
Drugs
rivaroxabanatorvastatin
03
Conditions
Myocardial injury
Beyond the preview
Go deeper on NCT06961630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961630.